Levosimendan Kalceks

Levosimendan, the active ingredient in Levosimendan Kalceks, is a calcium sensitizer and potassium channel opener presented as an injectable solution for intravenous use. It is used to improve cardiac contractility in patients with acute decompensated heart failure.

GNH USA supplies Levosimendan Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Levosimendan acts as an inotropic agent for conditions involving impaired cardiac output.

Acute decompensated heart failure: improves cardiac output and reduces symptoms of congestion. Low cardiac output syndrome: enhances myocardial contractility without increasing intracellular calcium. Post‑cardiac surgery low output: supports hemodynamics during weaning from mechanical support.

Levosimendan may be associated with several adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: reduction in blood pressure, especially with rapid infusion. - Nausea: occasional gastrointestinal upset. - Tachycardia: increased heart rate during treatment.

Serious or Rare Side Effects: - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischemia: chest pain or ECG changes indicating reduced coronary perfusion. - Severe hypotension: marked drop in blood pressure requiring intervention. - Allergic reactions: rash, itching, or anaphylaxis in susceptible individuals.

Levosimendan should be used with careful clinical monitoring.

Renal impairment: monitor dosing and renal function. Hepatic impairment: use with caution and assess liver enzymes. Hypotension: avoid rapid infusion in patients with low baseline blood pressure. Concomitant vasodilators: assess for additive hypotensive effect. Pregnancy: safety not established; weigh benefits against potential risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levosimendan may interact with several drug classes.

Major Interactions (Avoid): - Sodium nitroprusside: additive vasodilation can cause severe hypotension. - Phosphodiesterase inhibitors (e.g., milrinone): increased risk of profound hypotension. - Beta‑blockers: may blunt the intended inotropic response.

Moderate Interactions (Monitor Closely): - ACE inhibitors: monitor blood pressure for additive effects. - Diuretics: adjust fluid balance and electrolytes as needed. - Calcium channel blockers: observe for potential arrhythmias.